Careers | GSK US Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. Hwee J, Smith S, Small M, et al. Bogart M, Bancroft T, Rothnie K, et al. POSTER: Lokhandwala et al. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Cancer Immunol Immunother. and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. Curr Opin Pharmacol. P1481. 2017;31(2):101-1261. GSK Solid Tumor Oncology Account Manager; Long Island East, NY Long Island-Queens 30d+ $160K-$216K Per Year (Employer est.) 2017;35(15):suppl TPS3113. BCMA is essential for the survival of long-lived bone marrow plasma cells. [Poster No. POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR, 2. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1? POSTER: A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, 1. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. to let us know you're having trouble. Further details on cookies and how to object to their placement can be found in our Cookie Policy. EU Medical Affairs Lead, Hematology - jobs.gsk.com Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis ?of REALITI-A? Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? We support smart risk-taking while doing the right thing, invest in innovation where and when it matters, and constantly strive to do things better to make an impact on peoples health across the world. 8. Gsk Medical Jobs in London | Indeed.com Upload your CV and easily apply to jobs from any device! 2004;199(1):91-98. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. ORAL PRESENTATION: Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY), 1. [Poster No. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Zejula [summary of product characteristics]. Schwarz TF et al. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. 3. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment, 5. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. (Poster No. 2. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail Wenn Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Genes Dev. GSK Medical Affairs Salaries | Glassdoor Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Obeid D, Bansal S, Brown N, et al. P1512. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. Experienced professionals | GSK Global Medical Affairs Director - Neurosciences Job in London, ENG at GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). The winners found large companies with a big Hispanic workforce and created solutions including an employer caregiver toolkit and caretaker programs. Se continui a visualizzare When expanded it provides a list of search options that will switch the search inputs to match the current selection. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with anti?PD-1 therapy in advanced solid tumors. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. 12. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Our HR team works with external experts to define best practices. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. Front Immunol. 2. Poster No. [Poster No. Ismaila A, Czira A, Haeussler K, et al. 8. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Poster No. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, 27. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the worlds health. and physicians? 5. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. perspective on the burden of Hypereosinophilic Syndrome. Nous sommes dsols pour la gne occasionne. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. [Poster No. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. Eur J Immunol. Rothnie K, Han X, Bancroft T, et al. Bogart M, Chastek B, White J, et al. Lan Y, Zhang D, Xu C, et al. Did this answer your question? 9. This effort supports employees by enhancing their strengths and addressing any development gaps through individual and group coaching and sponsorship. Hahn B, Bogart M, Silver J, et al. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. POSTER: A Phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas (Presentation Posted With Permission), 1. Waikar SS, et al. 2. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. Bogart M, Wu B, Germain G, et al. Click to select your career area and upload your resume. We use cookies to personalise content and ads, to provide social media features and to analyse our websites. Anzueto A, Obeid D, Bansal S, et al. Review the package insert for important safety information. Gsk Medical Affairs jobs Sort by: relevance - date 55 jobs EU Medical Affairs Lead, Hematology GSK 4.1 Brentford TW8 Leverage your professional network, and get hired. Trademarks are owned by or licensed to the GSK group of companies. 4. You are using an unsupported browser.Some features of this site may not function properly. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448). Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor ? 3. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. We also share information about your use of our site with our advertising, social media and analytics partners. Pollard S, Offenberger J, Lee FE-H, et al. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. Paclitaxel Versus Placebo + Carboplatin?Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. Note: The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. Bell CF, et al. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. P806; Abstract A4295]. 2018;9:947. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. ASCEND program: efficacy and safety from ASCEND-D and ?ND, and overall MACE findings, 1. Ramesh N, Hegewald M, Maselli DJ, et al. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. Gupte R, Liu Z, Kraus WL. Please help us protect Glassdoor by verifying that you're a Prez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. Watch the video here: gsk.to/3KQpI7P, Today is the day! Strobel M, Alves D, Roufosse F, et al. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. Reasons why patients with severe asthma discontinue biologic treatment, Impact of mepolizumab in patients with life-threatening asthma, CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting ?2-agonist therapy, Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys, CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial, Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting ?2-agonist, Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation, Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population, Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation, Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial, Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial, Benefit?risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model, Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components, Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians, Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD), Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population, Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs, Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network, Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018, Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. P787; Abstract A5625]. Blood. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. 2018;22(4):343-351. 2019;7(4):559-571. By clicking this link, you will be taken to a website that is independent from GSK. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). Therapeutic Mularski RA, Drummond MB, Jain R, et al. GSK plc. Aiutaci a proteggere Glassdoor dimostrando che sei una persona reale. 493), 3. 10. Poster No. Affairs portal to a separate website maintained by ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. The estimated base pay is $154,315 per year. J Clin Invest. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. 2016;7(41):67532-67550. ?Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. naar Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France??
Simran Kooner Dentist,
How Long Does Reddi Whip Last On A Pie,
Live In Apartment Manager Jobs San Diego,
What Can I Do With Leftover Mussel Broth,
How To Represent In Hexadecimal,
Articles G